Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Nutricia Launches Nutra Neocate, Weaning Product Designed For Cows' Milk Protein Allergy
Nutricia, the European market leader in advanced medical nutrition, has announced the launch of Neocate Nutra, the first and only weaning product made from 100% non-allergenic amino acids. Neocate Nutra has been specifically developed for weaning infants and older children with cows" milk protein allergy (CMPA) and multiple food protein intolerance (MFPI). Unlike many weaning products, Neocate Nutra contains no hidden allergens and is designed to provide children with the key essential nutrients they need for development. With its unique format, Neocate Nutra is suitable for taking infants through the various stages of weaning and also for older children on very restricted diets who are looking for convenient and varied food options.
buy viagra
Need Something? Talk To My Right Ear!
We humans prefer to be addressed in our right ear and are more likely to perform a task when we receive the request in our right ear rather than our left. In a series of three studies, looking at ear preference in communication between humans, Dr. Luca Tommasi and Daniele Marzoli from the University "Gabriele d"Annunzio" in Chieti, Italy, show that a natural side bias, depending on hemispheric asymmetry in the brain, manifests itself in everyday human behavior. Their findings were just published online in Springer"s journal Naturwissenschaften.
News of the day
Reminder Program Dramatically Increases Mammography Rates, Kaiser Permanente Study Finds
A reminder program aimed at screening for breast cancer when it is most treatable boosted mammography rates by more than 17 percentage points, according to a new study by Kaiser Permanente"s Center for Health Research in the August issue of the American Journal of Preventive Medicine. The program used electronic health records to identify women who would soon be due for a mammogram and reached out to them via postcards, automated voice messages and personal phone calls.
Mental Health

Figuring Out Who Will Benefit Most From A New Therapy For Multiple Sclerosis

In a recent phase II clinical trial, the drug alemtuzumab (Campath-1H) was found to be a highly effective treatment for individuals with early relapsing-remitting multiple sclerosis. However, a substantial proportion of the patients treated (30%) went on to develop another autoimmune disease, mostly thyroid autoimmunity. Now, Joanne Jones and colleagues, at the University of Cambridge, United Kingdom, have determined that individuals with higher levels of the soluble factor IL-21 in their blood prior to alemtuzumab treatment were those that went on to develop an autoimmune disease. Further analysis identified a mechanism by which IL-21 contributes to the development of autoimmunity and determined that in some patients the higher levels of IL-21 were genetically predetermined. The authors therefore suggest that measuring levels of IL-21 in the blood of individuals with early relapsing-remitting multiple sclerosis might identify those that would be at greatest risk of developing autoimmunity if treated with alemtuzumab. Terri Laufer and Gregory Wu, at the University of Pennsylvania, Philadelphia, further discuss the importance of this in an accompanying commentary, noting that determining one reason why some patients succumb to autoimmune disease after alemtuzumab treatment, while others do not, is likely to increase enthusiasm for this new therapeutic. TITLE: IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H) AUTHOR CONTACT: Joanne L. Jones University of Cambridge, Addenbrooke"s Hospital, Cambridge, United Kingdom. View the PDF of this article at: https://www.the-jci.org/article.php?id=37878 ACCOMPANYING COMMENTARY TITLE: Treating MS: getting to know the two birds in the bush AUTHOR CONTACT: Terri M. Laufer University of Pennsylvania, Philadelphia, Pennsylvania, USA. View the PDF of this article at: https://www.the-jci.org/article.php?id=39963 Karen Honey Journal of Clinical Investigation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009